



## Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS

May 24, 2018

DUBLIN, May 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on solriamfetol (JZP-110) and Xyrem® (sodium oxybate) oral solution at the Annual Meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, MD from June 3-6, 2018.

The live webcast will begin at 7:00 p.m. EDT on June 5, 2018. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at <http://www.jazzpharmaceuticals.com>. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

### Audio webcast/conference call:

U.S. dial-in number: +1 800 239 9838

International dial-in numbers: [click here](#)

Passcode: 5629915

An audio archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at <http://www.jazzpharmaceuticals.com>.

### About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase *Erwinia chrysanthemi*), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. For country-specific product information, please visit <http://www.jazzpharmaceuticals.com/products>. For more information, please visit <http://www.jazzpharmaceuticals.com/> and follow us on Twitter at [@JazzPharma](#).



 View original content with multimedia: <http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-webcast-discussion-of-data-to-be-presented-at-apss-300654535.html>

SOURCE Jazz Pharmaceuticals plc

Investors: Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887, U.S., +1 650 496 2717, or Media: Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations, Ireland, +353 1 697 2141, U.S., +1 215 867 4910